
The study evaluated the short-term effects of intravitreal dexamethasone implant (IDI) in diabetic macular edema (DME) patients unresponsive to anti-VEGF injections. A single IDI was administered, and outcomes were measured over hours to days. Results showed a significant decrease in central retinal thickness (CRT) within 24 hours, with some improvement observed as early as 3 hours post-implantation. Best-corrected visual acuity (BCVA) also improved over the one-month follow-up period. IDI appears effective for refractory DME, with rapid onset of action.
Like
Save
Share